U.S. markets open in 1 hour 5 minutes

Avenue Therapeutics, Inc. (ATXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4100-0.0100 (-0.41%)
At close: 4:00PM EDT
2.4500 +0.04 (1.66%)
Pre-Market: 07:31AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.4200
Bid2.4200 x 800
Ask2.4600 x 900
Day's Range2.4000 - 2.5000
52 Week Range2.2200 - 12.3400
Avg. Volume427,641
Market Cap40.363M
Beta (5Y Monthly)0.67
PE Ratio (TTM)N/A
EPS (TTM)-0.2970
Earnings DateAug 14, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • TipRanks

    Monday’s Pre-Market: Here’s What You Need to Know Before the Market Opens

    U.S. stock futures jumped on Monday as investors await comments from the Fed members at an Official Monetary and Financial Institutions Forum panel, to be held virtually. Additionally, the monthly Chicago Fed National Activity Index for May will be released today. S&P, Dow, and Nasdaq futures were in the green at the time of writing, with 0.5%, 0.3%, and 0.3% higher trading, respectively. NextDecade Corporation (NEXT), Pluristem Therapeutics (PSTI), Avenue Therapeutics Inc. (ATXI), and Hancock J

  • Reuters

    CORRECTED-U.S. FDA declines to approve Avenue's painkiller again, shares drop

    Avenue Therapeutics Inc said on Monday the U.S. Food and Drug Administration had once again declined to approve its painkiller tramadol, sending its shares about 5% lower in premarket trading. The health regulator had previously declined to approve the painkiller in October, stating that it was not safe for the intended population. The agency said the delayed and the unpredictable onset of analgesia - relief from pain - with intravenous (IV) tramadol does not support its benefit as a monotherapy to treat patients with acute pain.

  • Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

    Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

    NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) seeking approval for IV tramadol. The CRL stated that the delayed and unpredictable onset of analgesia with IV tramadol does not support its